Rafael Holdings FY 2026: Revenue $874K, Net loss $29.6M — 10-K Summary
Rafael Holdings reported FY 2026 revenue of $874K, with healthcare revenue at $519K and real estate rental revenue at $355K. Net loss narrowed to $29.6M from $30.5M, but operating loss widened to $33.4M due to higher healthcare R&D spending. The company completed a Phase 3 trial for Trappsol Cyclo and submitted an NDA, pending FDA review.
How this was made
The 30-second read
Why it matters
The earnings beat on loss reduction may provide short‑term support, but the company still faces operating deficits and pending regulatory decisions.
Market read
Primary micro‑cap earnings release with modest financial improvement; limited broader market impact.
What to watch
The pending FDA review of Trappsol Cyclo could be a catalyst if approval is granted, but current uncertainty tempers immediate upside.
Background
Rafael Holdings, a micro‑cap biotech and real‑estate operator, released its FY 2026 10‑K highlighting a $874K revenue total and a narrowed net loss.
Ticker impact
Rafael Holdings filed its FY 2026 10‑K showing a narrowed net loss to $29.6M and a modest revenue increase.
slight upside as investors digest the loss improvement
The company posted a smaller net loss year‑over‑year while revenue grew, which could attract value‑oriented buyers despite ongoing operating deficits.
Market effects
Minimal impact on the broader healthcare and real‑estate sectors; micro‑cap biotech earnings rarely move peers.
Limited to U.S. micro‑cap market; no broader regional effect.
Low global relevance; the filing is company‑specific.
Counterpoint
Despite loss narrowing, the ongoing operating loss and modest revenue suggest the stock may remain pressured.
Key entities
- companyRafael Holdings
Issuer of the FY 2026 10‑K filing.
